Brind.

AngioDynamics appoints new CEO amid Q1 earnings report

2 reports, 2 independent Updated Oct 8
Gone quiet Reached 2 outlets in its first 24 hours
Reports
2
Developments
1
Repetition
50%

New informationRepeats or wire copies

AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Eric Honroth, Global President of Life Science at Getinge, was named the new CEO of AngioDynamics. AngioDynamics reported Q1 earnings that beat analyst forecasts for sales and pro forma loss, but the company's stock tumbled 20.7%.

From aol.com

Why it matters

Some supportBrind's analysis of the reports

The leadership change comes after AngioDynamics experienced six consecutive years of losses. Although the company exceeded revenue expectations, its year-over-year growth was only 6.9%, and its GAAP loss was $0.17 per share.

From aol.com

Who's involved

  • GetingeEmployer of Eric Honroth, who was named CEO of AngioDynamics

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped